Samsung Biologics Co., Ltd.August 24, 2021

FDA 483 - Samsung Biologics Co., Ltd. - August 24, 2021

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Samsung Biologics Co., Ltd.

Record Details

Samsung Biologics Co., Ltd., a drug substance manufacturer in Incheon, Republic of Korea, was cited with two observations during an FDA inspection. The inspection revealed deficiencies in cleaning validation processes, specifically regarding cross-contamination assessments and dirty hold time studies. Additionally, the firm failed to adequately investigate discrepancies to identify root causes and implement effective corrective actions, as evidenced by issues with mold detection and bioburden testing procedures.

Company: Samsung Biologics Co., Ltd.
Inspection Date: August 24, 2021
Product Type: Drugs
Office: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)
People: Chen Sun
Yun Wu

Open in Dashboard

ID · 1438e64e-df97-414c-bdce-bd6137243e90